BAO PHARMA-B (02659) announced that it repurchased 184,800 shares on August 31, 2026, for a total consideration of approximately HK$2.9912 million.
The buyback was executed at a per-share price ranging from HK$15.69 to HK$16.66.
BAO PHARMA-B (02659) announced that it repurchased 184,800 shares on August 31, 2026, for a total consideration of approximately HK$2.9912 million.
The buyback was executed at a per-share price ranging from HK$15.69 to HK$16.66.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。